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Abstract
Background: To understand the complex and largely not well-understood apoptotic pathway and immune system
evasion mechanisms in hepatitis C virus (HCV)-associated hepatocellular carcinoma (HCC) and HCV associated
chronic hepatitis (CH), we studied the expression patterns of a number of pro-apoptotic and anti-apoptotic genes
(Fas, FasL, Bcl-2, Bcl-xL and Bak) in HepG2 cell line harboring HCV- genotype-4 replication. For confirmation, we
also assessed the expression levels of the same group of genes in clinical samples obtained from 35 HCC and 34
CH patients.
Methods: Viral replication was assessed in the tissue culture medium by RT-PCR, quantitative Real-Time PCR (qRT-
PCR); detection of HCV core protein by western blot and inhibition of HCV replication with siRNA. The expression
level of Fas, FasL, Bcl-2, Bcl-xL and Bak was assessed by immunohistochemistry and RT-PCR whereas caspases 3, 8
and 9 were assessed by colorimetric assay kits up to 135 days post infection.
Results: There was a consistent increase in apoptotic activity for the first 4 weeks post-CV infection followed by a
consistent decrease up to the end of the experiment. The concordance between the changes in the expression
levels of Fas, FasL, Bcl-2, Bcl-xL and Bak in vitro and in situ was statistically significant (p < 0.05). Fas was highly
expressed at early stages of infection in cell lines and in normal control liver tissues followed by a dramatic
reduction post-HCV infection and an increase in the expression level of FasL post HCV infection. The effect of HCV
infection on other apoptotic proteins started very early post-infection, suggesting that hepatitis C modulating
apoptosis by modulating intracellular pro-apoptotic signals.
Conclusions: Chronic HCV infection differently modulates the apoptotic machinery during the course of infection,
where the virus induces apoptosis early in the course of infection, and as the disease progresses apoptosis is
modulated. This study could open a new opportunity for understanding the various signaling of apoptosis and in
the developing a targeted therapy to inhibit viral persistence and HCC development.
Background
Hepatitis C virus (HCV) is a major worldwide causative
pathogen of chronic hepatitis, cirrhosis, and hepatocellu-
lar carcinoma [1]. Egypt has the highest prevalence of
H C Vi n f e c t i o ni nt h ew o r l dw h e r e1 5 %o ft h et o t a l
population are infected [2-4]. Although the exact
mechanisms of HCV pathogenesis, such as viral persis-
tence, hepatocytes injury, and hepatocarcinogenesis are
not fully understood, yet an accumulating body of
evidence suggests that apoptosis of hepatocytes is signif-
icantly involved in the pathogenesis [5,6].
Apoptosis plays a pivotal role in the maintenance of
cellular homeostasis through removal of aged cells,
damaged cells, and overgrowing new cells [7]. Failure of
apoptosis induced by various stimuli is one of the most
important events in tumor progression as well as in
resistance to cytotoxic therapy [8]. In mammalian cells,
apoptosis can be induced via two major pathways. First,
the death receptor pathway (extrinsic pathway), which is
triggered by binding Fas ligand (FasL) to Fas (CD95)
with subsequent activation of caspase-8, which in turn
activates the effectors caspases 3, 6, 7 [9-12]. This path-
way is considered an important apoptotic system in
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cules of cytotoxic T cells. The second apoptosis pathway
(the intrinsic pathway) is induced by mitochondria in
response to DNA damage, oxidative stress and viral pro-
teins [5]. Mitochondria-dependent apoptosis is amplified
by pro-apoptotic genes (Bax, Bad, Bak and others)
whereas molecules like Bcl-2 or Bcl-xL act as anti-apop-
totic. These proteins converge at the mitochondrial per-
meability transition pore that regulates the release of
apoptotic regulatory proteins, such as procaspase-9, and
cytochrome C [14].
There have been many studies indicating that apoptosis
of hepatocytes plays a significant role in the pathogenesis
of HCV infection [15], although various apoptotic path-
ways were proposed [16]. For example, many studies
demonstrated that HCV core protein suppresses apoptosis
mediated by cisplatin, c-myc, TNF-a, or the Fas signaling
pathway [17], whereas others showed that the core protein
sensitizes Fas, TNFa, or serum starvation-induced apopto-
sis [18]. The precise mechanisms for the involvement of
the HCV core protein on the apoptotic pathways are not
fully understood. For example, core protein-dependent
inhibition of TNF-a and CD95 ligand-induced apoptosis
has been described in a hepatoma cell line [19,20]. In
other models, overexpressed HCV core protein did not
prevent CD95 ligand induced apoptosis in hepatoma cells
or transgenic mice overexpressing HCV core protein
[17,21]. Until recently, the lack of an infectious HCV tissue
culture system did not allow to study the impact of HCV
infection on hepatocyte apoptosis [22].
T h ep r e s e n ts t u d yw a sp e r f ormed to determine the
changes in apoptotic machinery accompanying HCV
infection both in vitro and in vivo. For the in vitro study,
we developed a HCV replication system in HepG2 cell
line, which may reflect to some extent the in vivo situa-
tion. Successful infection and propagation of the virus
was assessed by detection of HCV-RNA using nested
RT-PCR with specific primers, detection of increased
titer by real time PCR, and virus passage to naïve cells.
The HCV-HepG2 cell line was then used to study the
long term effect of HCV infection on the apoptosis regu-
latory genes (Fas, FasL, Bak, Bcl-2, and Bcl-xL). This was
correlated with the apoptotic activity in the cells by
determining the expression levels of caspases 3, 8, and 9.
We further assessed protein expression and mRNA levels
of the same group of genes in liver tissues tissue samples
obtained from patients with chronic hepatitis (CH) and
hepatocellular carcinoma (HCC).
Methods
Patients
The present study included 69 cases that are HCV-RT-
PCR positive and HBV-PCR negative in both liver tis-
sues and serum samples. These cases were divided into
two groups: group 1 (HCC; n = 35), samples were col-
lected from patients diagnosed and treated at the
National Cancer Institute, Cairo University, between
December 2005 and August 2008; group 2 (CH; n = 34),
samples were collected from HCV associated chronic
hepatitis (CH) patients admitted to Kasr Al-Aini School
of Medicine, Cairo University, in the same period and
enrolled in routine diagnosis or therapeutic procedures.
The mean age of CH patients was 47.5 years and M:F
ratio was 1.5:1, whereas the mean age of HCC was 51.6
years and M:F ratio was 1.3:1.
All cases of CH were graded and staged according to
the modified Knodell scoring system [23] and all HCC
cases were graded according to the World Health Orga-
nization (WHO) classification criteria and staged
according to the American Joint Committee on Cancer
[24]. The percent of normal to tumor ratio were more
than 80% in all studied cases to overcome the nominali-
zation effect of the tumor stroma and/or necrosis as
well as the cirrhotic tissues factors in the studied speci-
mens. Table 1 illustrates the clinico-pathological fea-
tures of the studied cases. Normal liver tissue samples
were obtained from liver transplant donors (15 samples)
and were used as controls. A written consent was
obtained from all patients and normal liver donors prior
to enrollment in the study and the ethical committee of
Table 1 Clinical features of the studied groups of
patients.
Variables HCC CH
n = 35 (%) n = 34 (%)
Liver Function Test (Mean ± SD)
ALT 77.2 ± 76.2 74.33 ± 30.97
AST 70.577 ± 49.4 81.66 ± 35.35
Alk ph 181.1 ± 174.2 111.57 ± 61.58
Alb 3.758 ± 0.707 3.9 ± 0.538
T.Bil 1.1846 ± 0.523 1.34 ± 0.897
INR 1.179 ± 0.067 1.22 ± 0.161
Complete Blood Picture (Mean ± SD)
Hb 12.3 ± 1.64 13.59 ± 2.24
TLC 6.186 ± 3.163 6.509 ± 2.05
Plt 177 ± 121 175.5 ± 67.267
Viral marker
HBs-Ag 0 (0) 0 (0)
HCV-Ab 35 (100) 34 (100)
HBV-PCR 0 (0) 0 (0)
HCV-PCR 35 (100) 34 (100)
Tumor Marker (Mean ± SD)
Serum AFP 1885 ± 5888 265 ± 110
AFP, alpha fetoprotein; Alb, albumin; Alk, Alkaline Phosphates; ALT, alanine
aminotransferase; CH, chronic hepatitis; Hb, hemoglobin; HBs-Ag, hepatitis B
surface antigen; HCC, hepatocellular carcinoma; HCV, hepatitis C virus; INR,
International normalized ratio; PCR, polymerase chain reaction; Plt, platelet
count; TLC, total leukocytic count; T.Bil, total bilirubin.
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with the ethical guidelines of the 1975 Declaration of
Helsinki.
HepG2 cell culture
HepG2 cells were used to establish the in vitro HCV
replication. HepG2 culturing and infection were carried
out according to previous protocols [25]. Briefly, HepG2
cells were maintained in 75 cm culture flasks (Greiner
bio-one GmbH, Germany) containing Dulbecco’sM o d i -
fied Eagle’s Medium (DMEM) supplemented with 4.5 g/
L glucose and 10 g/L L-glutamine (Bio Whittaker, a
Combrex Company, Belgium), 50 ml/L fetal calf serum
(FCS), 10 g/L penicillin/streptomycin and 1 g/L fungi-
zone (250 mg/L, Gibco-BRL life Technologies, Grand
Island, NY (USA). The complete culture medium
(CCM) was renewed every 3 days, and cells were pas-
saged every 6-10 days. A total of 3 × 10
6 cells were sus-
pended in 10 ml CCM and incubated at 37°C in 5%
CO2.
Viral inoculation and sample collection
Viral inoculation and cell culture were performed as
previously described [26]. Briefly, cells were grown for
48 h to semi-confluence in complete culture medium,
washed twice with FCS-free medium, and then inocu-
lated with 500 μl serum obtained from HCV infected
patients (500 μl patient sera and 500 μlF C S - f r e e
DMEM/3 × 10
6 cells). The HCV genotype was charac-
terized as genotype-4 with 9 quasispecies based on our
previously described method [27]. The viral load in the
used serum was quantified by real time PCR. The aver-
age copy number was 58 × 10
7copies/ml. After 180 min,
Ham F12 medium (Bio Whittaker, a Combrex Com-
pany, Belgium) containing FCS was added to make the
overall serum content 100 ml/L in a final volume of 10
ml including the volume of the human serum, which
used for infection as mentioned above. Cells were main-
tained overnight at 37°C in 5% CO2.T h en e x td a y ,
adherent cells were washed with CCM and incubation
was continued in CCM with 100 ml/L FCS. Throughout
the culture duration, the assessment of HCV replication
were confirmed by a detection of viral core protein
using western blotting, by RT-PCR amplification of
sense and antisense strands of the virus by real time
PCR and by the inhibition of HCV replication using
siRNA knockout as we previously reported [28].
Western blot analysis of HCV core antigens in HepG2
cells
Lysates containing 100 μg of protein from uninfected
and infected HepG2 cells were subjected to SDS-PAGE,
as previously described [26,27]. After three washes,
membranes were incubated with diluted peroxidase-
labeled anti-human IgG/IgM antibody mixture at 1:5000
in PBS (3 g/L) for previously treated strips with the
anti-core antibody (Novocastra, Novocastra Labora-
tories, UK) for 2 h at room temperature. Visualization
of immune complexes on the nitrocellulose membranes
was performed by developing the strips with 0.01 mol/L
PBS (pH 7.4) containing 40 mg 3,3’,5,5’-tretramethylben-
zidine and 100 μl of 30 ml/L hydrogen peroxide (Immu-
nopure TMB substrate Kit, PIERCE, Rockford, IIIinois,
USA).
Quantification of human GAPDH mRNA
The integrity of the cellular RNA preparations from
HCV infected HepG2 cells was analyzed by 18s and 28s
bands on agarose gel and by automated gel electrophor-
esis (Experion Software Version 3.0, Bio-Rad), which
was also used for measuring the RNA concentration in
addition to spectrophotometer at 260 nm (nanoDrop,
USA). GAPDH mRNA levels were quantified by real
time RT-PCR using TaqMan technology with GAPDH
specific primers. Amplification of human GAPDH tran-
scripts was performed using the TaqMan EZ RT-PCR
kit (Applied Biosystems, Foster City, CA). The target
template was the purified cellular RNA from HepG2
cells at 1, 2, 3, 4, 5, 6, 7 and 8 days post-infection with
HCV, in absence and presence of siRNA. The RT-PCR
was performed using a single-tube, single-enzyme sys-
tem. The reaction exploits the 5’-nuclease activity of the
rTth DNA polymerase to cleave a TaqMan fluorogenic
probe that anneals to the cDNA during PCR 50 μl reac-
tion volume, 1.5 μl of RNA template solution equivalent
to total cellular RNA from 2.5 × 10
5 cells were mixed
with 200 nM forward primer, 200 nM reverse primer,
300 nM GAPDH probe, 300 μMf r o me a c ho fd A T P ,
dCTP, dGTP and 600 μMd U T P ,3m Mm a n g a n e s e
acetate, 0.5 μl rTth DNA polymerase, 0.5 μlA m pE r a s e
UNG, 1× Taqman EZ buffer and amplified in the
sequence detection system ABI 7700 (Applied Biosys-
tems, Foster City, CA). The RT-PCR thermal protocol
was as follows: Initial UNG treatment at 50°C for 2 min-
utes, RT at 60°C for 30 minutes, deactivation of UNG at
95°C for 5 minutes followed by 40 cycles, each of which
consists of denaturation at 94°C for 20 seconds and
annealing/extension at 62°C for 1 min.
Northern Blot Analysis
To construct a HCV RNA transcription vector total
RNA was extracted from all cell types at days 1, 2, 3, 4,
5, 6, 7 and 8 post-transfection, 5 μg of total RNA were
loaded onto the gel. HCV sequences from nt 47 to 1032
were cloned after RT-PCR into pSP 64 [poly(A)] vector
(Promega), resulting in plasmid PMOZ.1.HCV then con-
firmed by DNA sequence analysis. HCV template RNA
was transcribed in vitro from MOZ.1.HCV. Briefly, 5 mg
Zekri et al. Comparative Hepatology 2011, 10:4
http://www.comparative-hepatology.com/content/10/1/4
Page 3 of 14of plasmid DNA was linearized with a BglII. The linear
plasmid DNA was purified from an agarose gel and then
incubated with 50 U of SP6 RNA polymerase for 2 h at
37°C in the presence of 500 mM (each) ribonucleoside
triphosphates (GTP, ATP, UTP, and CTP), 100 U of
RNAsin, 10 mM dithiothreitol, 40 mM Tris-HCl (pH
7.5), 6 mM MgCl2, 2 mM spermidine, and 10 mM
NaCl in a total reaction volume of 100 μl. After tran-
scription reaction, DNA template was degraded by two
rounds of digestion with RNase-free DNase (Boehringer)
for 30 min at 37°C with 10 U of enzyme. Upon comple-
tion of digestion, two rounds of extraction with phenol-
chloroform-isopropyl alcohol and then ethanol precipi-
tation were done. HCV RNA transcripts, which con-
tained a poly(A) tail, were further purified on an oligo
(dT) cellulose column. RNA concentration was deter-
mined spectrophotometrically at A260 with UV light.
An aliquot was analyzed by agarose gel electrophoresis
to assess its integrity.
Sensitivity of RT-PCR assay
HCV RNA synthesized in vitro was diluted with TE
(Tris-EDTA) buffer at a concentration of approximately
106 copies per ml and was stored at -20°C. Serial 10-
fold dilutions of these stock solutions were made in
water just prior to RT-PCRs. One hundred copies were
routinely detected. Both probes were purified using
MicroSpin G-50 columns (Amersham Pharmacia). Blots
were visualized and quantified as previously described
[29].
Detection of plus and minus-strand RNA by nested RT-
PCR
Detection of plus- and minus- HCV strand was per-
formed as previously reported [26,30]. The One Step
real-time PCR system (Applied Biosystems) was used.
Molecular detection of HBV
DNA extraction and PCR amplification from fresh tis-
sues and PCR amplification were performed as pre-
viously described [31].
Determination of caspase activity
HepG2 cells were harvested on different dates. After
lysis and protein concentration, cell lysates containing
200 μg of total protein was used to measure the activ-
ities of caspases 3, 8 and 9 using ApoTaget colorimetric
Assay kits (BioSource international, Inc. Camarillo, CA)
according to the manufacturer instructions.
RNA extraction from liver tissues
Total RNAs were extracted using a SV total RNA isola-
tion system (Promega, Biotech) according to manufac-
turer’s instructions. The extracted total RNA was
assessed for degradation, purity and DNA contamination
by a spectrophotometer and electrophoresis in an ethi-
dium bromide-stained 1.0% agarose gel. Ten samples of
normal human DNA and RNA were extracted from nor-
mal liver tissues and were used to optimize the best
conditions for the multiplex PCR of B-actin gene (621-
bp fragments) versus each of the studied genes. Negative
RT-PCR control was used against each sample [32].
c-DNA synthesis
Reverse transcription (RT) of the isolated total RNA was
performed in 25 μl reaction volume containing 200 u of
Superscript II RT enzyme (Gibco-BRL, Gaithersburg,
MD, USA.), 1× RT-buffer [250 mM Tris-HCl pH 8.3,
3 7 5m MK C l ,1 5m MM g C l 2 ] ,1m Md i t h i o t h e r i t o l ,2 5
ng from random primer, 0.6 mM deoxynucleotide tri-
phosphates, 20 U RNAsin (Promega, USA.), 100 ng of
extracted RNA. Samples were then incubated at 50°C
for 60 min followed by 4°C until the PCR amplification
reaction [32].
PCR amplification of the studied genes
Primer sequences, PCR conditions of the studied genes
(Fas, FasL, Bcl-2, Bcl-xL and Bak), and the expected
PCR DNA band length are listed in Table 2. The PCR
and quantitation were performed in a 50 μLr e a c t i o n
volume containing 5 μL of the RT reaction mixture (c-
DNA), 2.5 units Taq polymerase (Gibco-BRL, Gaithers-
burg, MD, USA), 1× PCR buffer (500 mM KCl, 200 mM
Tris-HCl, 1.5 mM MgCl2, 1 mg/mL bovine serum albu-
min (BSA)), 200 mM each of the deoxyribonucleotide
triphosphate and 0.25 mM of each primer. Amplification
of the b-actin gene (621 bp fragment) was performed to
test for the presence of artifacts and to assess the quality
of RNA. A water control tube containing all reagents
except c-DNA was also included in each batch of PCR
assays to monitor contamination of genomic DNA in
the PCR reagents. Negative RT-PCR control was used
against each sample [32].
Table 2 Primer sequences of the studied genes.
Gene
Name
Primer Sequence Fragment
Length
b-actin 5’-ACA CTG TGC CCA ACG AGG-3’
5’-AGG GGC CGG TCA T AC T-3
621 bp
Fas 5’-GCAACACCAAGTGCAAAGAGG-3’
5’-GTCACTAGTAATGTCCTTGAGG-3’
265 bp
FasL 5’- ATGTTTCAGCTCTTCCACCTACAGA-3’
5’-CCAGAGAGAGCTCAGATACGTTGAC-3’
255 bp
Bak 5’-TGATACCTGTGCTTTATCCC -3’
5’- AAACCAGCATCTCTCTAAAC-3’
250 bp
Bcl-2 5’ GCAGATCCAGGTGATTCTCG 3’
5’ ATCGATGCCAATGACAGCCA 3’
234 bp
Bcl-XL 5’-CCCGGTGCTGCAGCATGTCCT -3’
5’-TCCCCTCGAGGATTTCGACAG -3’
521 bp
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Fifteen microliters of each PCR product were separated
by electrophoresis through a 2.0% ethidium bromide-
stained agarose gel and visualized with ultraviolet light.
Gels were photographed and the bands were scanned as
digital peaks. Areas of the peaks were then calculated in
arbitrary units with a digital imaging system (Photo-doc-
umentation system, Model IS-1000; Alpha Innotech Co.,
San Leandro, CA, USA). To evaluate the relative expres-
sion levels of target genes in the RT-PCR, the expres-
sion value of the normal pooled liver tissues was used as
a normalizing factor and a relative value was calculated
for each target gene amplified in the reaction. Non-
expression in any of the studied genes was considered if
there was a complete absence, or more than a 75%
decrease in the intensity of the desired band in compari-
son to the band of normal pooled liver tissue [24,25].
Samples were assayed in batches that included both
cases and controls. The absence of bands was confirmed
by repeating the RT-PCR twice at different days and by
consistent presence of b-actin gene amplification [32].
Immunohistochemistry
Protein expression of the studied proteins was assessed
using the following monoclonal antibodies Fas (C236),
FasL (sc-56103), Bcl-2 (sc-56016), and Bcl-xL (sc-8392)
(all from Santa Cruz Biotechnology, inc. Germany).
Briefly, from each tumor block, a hematoxylin and eosin-
stained slide was microscopically examined to confirm
the diagnosis and select representative tumor areas. Tis-
sue cores with a diameter of 1.5 mm were punched from
the original block and arrayed in triplicate on 2 recipient
paraffin blocks. Five μm sections of these tissue array
blocks were cut and placed on positive charged slides to
be used for IHC analysis. Sections from tissue microar-
rays were deparaffinized, re-hydrated through a series of
graded alcohols, and processed using the avidin-biotin
immunoperoxidase methods. Diamino-benzidine was
used as a chromogen and Mayer hematoxylin as a
nuclear counterstain. A case of follicular lymphoma was
used as a positive control for Bcl-2, Fas and FasL whereas
a case of colon cancer was used as a control for Bcl-xL.
Results were scored by estimating the percentage of
tumor cells showing characteristic cytoplasmic immunos-
taining for all examined markers [33].
Protein expression was classified compared to nor-
mal hepatic tissue samples. Positive expression was
further classified according to the level of expression
into mild: ≥ 10%- < 25%, moderate: ≥ 25%- < 50% and
high expression: ≥ 50% but during statistical analysis
they were broadly classified into negative or positive
expression.
Statistical analysis
The results were analyzed using the Graph Pad Prism
software (Graph Pad Software, San Diego, CA, USA).
For gene expression analysis the Mann-Whitney U Test
was used for numeric variables and Chi square or Fish-
er’s exact Test were used to analyze categorical vari-
ables. P-value was considered significant when ≤ 0.05.
Results
All studied cases were positive for HCV infection by
both ELISA and HCV RT-PCR in serum and liver tissue
but were negative for HBV infection by serological mar-
kers and PCR both in serum and liver tissues. The level
of pro-apoptotic genes expression was measured in
HCV infected HepG2 cell line as an in vitro model as
well as in HCC and CH tissue samples.
Infection of HepG2 cell line with hepatitis C virus
In this model, we observed a good correlation between
persistence of HCV infection in HepG2 cell line and the
appearance of certain morphological changes in the
infected cells such as visible cell aggregation and granu-
lation that took place 21 days post infection suggesting
successful viral transfection, as shown in Figure 1. Suc-
cessful HCV genotype-4 replication in HepG2 cells were
also confirmed by western blot for the detection of viral
core protein as shown in Figure 2a, as well as inhibition
of HCV replication by 100 nM siRNA previously devel-
oped in our lab [28], illustrated in Figure 2b.
Quantification of HCV RNA was performed both in
cell free media and cell lysates at days 1, 2, 3, 7, 14, 21,
28, 35, 42, 52, 59 and 116 post HCV infection. HCV
RNA was detected in all of these days except days 35,
52 for cell free media and days 21, 28 for cell lysates.
HCV-RNA was quantitatively detected in all days except
days 2, 3, 14, 45 (Table 3).
Apoptotic genes expression in HCV-infected HepG2 cells
No changes in the expression level of Bcl-2 gene post-
HCV infection was observed compared to the control
(HCV free HepG2 cells) (Figure 3A). The expression of
Bcl-xL and Bak genes (Figures 3B, C, respectively) fluc-
tuated 3 weeks post infection then, the levels of their
expression was similar to the control levels at the end of
the experiment. Interestingly, there was a good correla-
tion between Fas, FasL genes expression and HCV infec-
tion. The expression of Fas gene was visible until the
third measurement (day 3) post infection and then dis-
appeared by the end of the experiment. In contrast, the
expression of FasL was not visible until day 21 post
infection then the visibility progressively increased until
the end of the experiment (Table 3 Figures 3D, E).
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As shown in Figure 4, recognizable changes were
observed in caspases 3, 8 and 9 throughout the course
of HCV infection. There was an initial increase in their
levels starting from day six to day 30 then all caspases
levels were dramatically decreased until day 135 post-
infection.
Apoptotic genes expression in the studied cohorts of
patients
There was a significant difference in the RNA expres-
sion level of both Bcl-xL and Bcl-2 genes between HCC
and CH (26%, 80% versus 0%, 59%; respectively, p <
0.0001, = 0.0068). As well as between HCC cases and
normal distant tumor (NDT) (p < 0.001) (Figure 5).
Similarly, a significant difference was found in the Bak
gene expression between HCC and CH patients (69%
versus 47%, p = 0.0025) as well as between HCC and
NDT (p < 0.0001). The FasL was significantly expressed
in CH compared to HCC (47% versus 23%, p < 0.001).
None of the CH cases studied revealed Bcl-xL gene
expression.
Apoptotic proteins expression
Positive immunostaining for Bcl-2, Bcl-xL, Fas and
FasL proteins was detected in 29 (85.9%), 12 (34.3%),
21 (60%) and 9 (25.7%) the studied samples of the 35
HCC cases examined compared to 18 (52.9%), 0 (0%),
18 (52.9%) and 18 (52.9%) of samples of the 34 CH
cases; respectively. The concordance between immuno-
histochemistry and RT-PCR ranged from 86% to 94%
(Figure 6).
A B
Figure 1 (A): Non-infected HePG2 cells. (B): Infected HePG2 cells. Scale bar = 100 μm.
Figure 2 Expression levels of the viral core and GAPDH. (A) The expression level of the viral core and GAPDH in HepG2 cells infected by
HCV genotype-4 from day 1 to day 8. (B) The expression level of the viral core in HepG-2 cells infected by HCV genotype-4 from day 1 to day 8.
Upper row show HCV-core expression in un-transfected cells. Lower row showed the HCV- core expression in siRNA-Z5 transfected cells.
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Qualitative/Quantitative PCR (copy number/ml) Apoptotic gene
Days Cell free media Cell lysate Bcl-xL Bcl-2 Bak Fas FasL
Day1 Positive/785 Positive - + +++ ++ -
Day2 Positive/Negative Positive - + + ++ -
Day3 Negative/Negative Positive - + ++ ++ -
Day7 Positive/13005 Positive - + + - -
Day14 Positive/Negative Positive - + + - -
Day21 Negative/6782 Positive - + - - +
Day28 Negative/24678 Positive + + ++ - +
Day35 Positive/8892 Negative - + - - +
Day45 Positive/Negative Positive + + - - ++
Day52 Positive/7374 Negative - + - - +++
Day59 Positive/22963 Positive + + ++ - +++
HepG2 Control - - - + + + -
+: Equal to the expression level in the HepG2; ++: twofold increase in the expression level; +++ threefold increase in the expression level.
265 bp
Cycle
Amplification  Plot
Figure 3 Data on gene amplification. Ethidium bromide-stained 2% agarose gel (A) for Bcl2 gene amplification. Lanes 1 and 2 showed
negative RT-PCR control; lane 3 showed positive amplification of CH case; lane 4 showed negative amplification of CH case; lane 5 showed
positive amplification of HCC case; lane 6 showed negative amplification of HCC case; lane 7 showed positive amplification of HepG2 without
HCV infection; lane 8 showed positive amplification of HepG2 with HCV infection. (B) For Bcl-Xl gene amplification. Lane 1 showed HepG2-
positive amplification with HCV infection at day 28; lane 2 HepG2-negative amplification without HCV infection; lane 3 and 4 showed positive
amplification of CH case; lane 5 showed positive amplification of HCC case; lane 6 & 7 showed negative RT-PCR control. (C) For Bak gene
amplification. lane 1 HepG2-positive amplification with HCV infection at days 59; lane 2 HepG2-negative amplification without HCV infection lane
3 showed HepG2-negative amplification with HCV infection at days 35; lane 4 showed positive amplification of CH case; lane 5 showed positive
amplification of HCC case of CH; lane 6 negative RT-PCR control. (D) for Fas gene amplification, first lane: MW, lanes 1 and 2: negative RT-PCR
control, lane 3 showed HepG2-positive amplification without HCV infection, lane 4 HepG2- showed negative amplification with HCV infection at
day 21, lane 5 showed negative case of HCC, lanes 6 and 7 showed positive amplification of CH and lane 8 showed positive amplification of
HCC case. (E) for FasL gene amplification, lane 1: negative RT-PCR control; lanes 2 and 3 showed HepG2-positive amplification with HCV infection
at days 28 and 35 respectively; lane 4 showed HepG2-negative amplification without HCV infection; lane 5 showed negative case of CH; lanes 6
and 7 showed positive amplification of CH, lanes 8 and 9 showed positive amplification of HCC case. (F) Amplification plot of RT-PCR for
housekeeping gene using Taqman probe.
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In HCC cases, Fas-RNA and protein expression were
significantly associated with the presence of cirrhosis (p
= 0.0027) and with poorly differentiated tumors (p <
0.0001). Bak gene expression was significantly associated
with the presence of invasion (p = 0.05), absence of cir-
rhosis (p < 0.0001) and with well differentiated tumors
(p < 0.0001). The expression level of Bcl-2-RNA and
protein was significantly associated with poorly differen-
tiated tumors (p < 0.0001) (Table 4).
Table 5 shows that in CH patients Fas expression was
significantly associated with high hepatitis grade (p =
0.05), whereas FasL expression was significantly asso-
ciated with the presence of necrosis as well as with high
hepatitis grade and stage (p = 0.015, 0.015 and 0.006;
respectively). In contrast, Bcl-2 expression was
Figure 4 Changes in caspases expression levels in vitro.
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(p < 0.0001).
Discussion
An important cause of morbidity and mortality world-
wide is the infection by HCV. Progress in understanding
HCV biology has remained challenging due to the lack
of an efficient cell culture system for virus growth.
Establishment of self-replicating full-length HCV geno-
mic replicons from genotypes in cultured cells has pro-
vided an important tool for the study of HCV
replication mechanisms. This study discusses the system
for the HepG2 cell line harboring HCV- genotype-4
replication and examines the expression levels of group
of genes in clinical samples obtained from HCC and CH
patients. Other studies have reported another systems
for HCV replication, the first with HCV GT1 H77 in
immortalized human hepatocytes (IHH) [34] and the
o t h e rs y s t e mo fH C VG T 2J F H 1i nh u m a nh e p a t o m a
cell line (Huh7) [35]. Kanda et al. s u g g e s t e dt h a tI H H
support HCV genome replication and virus assembly by
examined HCV core protein-mediated IHH for growth
of HCV [34]. Their study described the generation of
cell culture-grown HCV from genotype 1a and discuss
the concept of HCV replication and assembly of geno-
type 1a in IHH and speculated that cellular defense
mechanisms against HCV infection are attenuated or
compromised in IHH [34]. It was reported the HCV
production from a HCV-ribozyme construct of genotype
1a (clone H77) in Huh-7 cells with no determination for
the virus infectivity [35]. Furthermore, subgenomic
replicons of the JFH1 genotype 2a strain cloned from an
individual with fulminant hepatitis replicate efficiently in
cell culture. The JFH1 genome replicates efficiently and
supports secretion of viral particles after transfection
into a Huh7, providing a powerful tool for studying the
viral life cycle and developing antiviral strategies [35].
Apoptosis has been demonstrated as an important
mechanism for viral clearance. In HCV-infected liver,
viral persistence is observed despite enhanced hepato-
cyte apoptosis [5]; however, it is not clear whether this
apoptotic effect is due to a direct cytopathic effect of
the virus, immunological reactions or a contribution of
the molecular mechanisms causing liver damage during
HCV infection [22,36]. For understanding the impact of
HCV infection on the apoptotic machinery during dis-
ease progression, we studied the expression patterns of
B c l - 2 ,B c l - x L ,B a k ,F a s ,F a s Li nH C V -g e n o t y p e - 4
infected HepG2 cell line as well as in human tissue sam-
ples obtained from patients with HCC and CH as a
result of chronic HCV infection. We also analyzed the
expression levels of caspases 3, 8 and 9 in tissue culture
medium and in HCV infected cells by a colorimetric
assay, and viral replication by both RT-PCR and Real-
Time PCR for up to 135 days post-infection.
The results of the present study showed that HCV
infection disrupted the process of apoptosis through
down regulation of Fas and up-regulation of FasL genes
expression. However, in tissue samples a higher expres-
sion of Fas and FasL genes were detected in CH com-
pared to HCC patients, which explains the presence of
severe inflammation in chronic HCV infection and its
oncogenic potential. In this regard, previous studies
demonstrated that enhanced FasL gene expression
induces T-cell apoptosis [15], which favors viral persis-
tence and indirectly increases the probability of progres-
sion to HCC [36]. In addition, the FasL gene exerts
proinflammatory activities via IL-1b secretion that is
responsible for neutrophils infiltration [37].
In contrast, other studies [38-40] demonstrated that
the ratio of Fas/FasL was significantly lower in HCC
than in CH tissue samples or non tumor hepatic tis-
sues. This was attributed to the fact that tumor cells
possess more than one safe guard against Fas mediated
apoptosis. First, the reduced expression or loss of cer-
tain molecules that are involved in the Fas mediated
apoptosis pathway such as FADD (Fas-associated pro-
tein with death domain), FLICE (FADD like interleu-
kin-1b-coverting enzyme, caspase-8) or FAF (Fas
associated factor), or the induction of molecules that
would inhibit Fas mediated apoptosis such as FAP (Fas
associated phosphatase) [7]. Second, the expression of
sFas RNA and FAP-1 may neutralize Fas mediated
apoptosis [41] and third, Fas mutation could be
expected. Many investigators suggested that one of the
possible mechanisms by which HCV core protein inhi-
bits apoptosis is through a direct binding to down-
stream domain of FADD and cFLIP leads to viral
persistence and cells proliferation [5]. Consequently, it
is conceivably possible that the observed decreased
Figure 5 The expression level of the apoptotic genes in the
different studied groups. NB: CH = Chronic hepatitis, HCC =
Hepatocelullar carcinoma, NAT = Normal distant to tumor.
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Figure 6 Cases of chronic hepatitis (CH) and hepatocellular carcinoma (HCC). Data from cases of CH showing (A) high membranous
expression of FasL, (B) moderate cytoplasmic expression of FAS and (C) moderate cytoplasmic expression of Bcl-2. Cases of HCC showing (D)
High membranous expression of FasL, (E) Marked expression of FAS, (F) high expression of Bcl-2, and (G) Marked expression of Bcl2 in tumor
tissues with loss of expression in adjacent non neoplastic region. Scale bar = 100 μm (A, C, D, G) and 200 μm (B, E, F).
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tocytes could be part of the signaling mechanisms in
the pathogenesis of HCC [42].
It has also been reported that the extrinsic (Fas-FasL)
pathway plays an important role in liver cell injury
directly via HCV infection or indirectly through immune
attack of HCV- infected cells with subsequent recruit-
ment and activation of stellate cells and macrophages,
resulting in fibrosis and cirrhosis [43]. Also, I was found
that during HCV infection, HCV-specific T cells migrate
to the liver and recognize viral antigens on the hepato-
cytes [38]. These immunologically active cells, which are
probably induced due to inflammation rather than viral
infection, become activated and express FasL that trans-
duces the apoptotic death signal to Fas bearing hepato-
cytes, resulting in their destruction [38]. Therefore,
neither Fas expression nor the degree of liver injury cor-
relates with the intra-hepatic viral load [15,44]. In such
case, the TNF or the IFN-δ might be responsible for the
up regulation of Fas expression in infected hepatocytes
and FasL in lymphocytes [45].
Alternatively, the hepatocytes which are likely type II
cells in which direct activation of caspase 8 (extrinsic
pathway mechanism) is not sufficient to induce apopto-
sis amplification by a mitochondrial pathway (intrinsic
mechanism) are highly required. Accordingly caspase 8
activation causes the proapoptotic cleavage of Bid,
which induces cytochrome c release from the mitochon-
dria, which subsequently binds to Apaf-1 and procas-
pase 9 forming apoptosome complex [29]. In the
present study, we assessed the activation of caspases 8,
and 9, which represent both death receptor-mediated
and the mitochondrial apoptosis pathway and caspase 3
which is an executioner caspase. Our data showed a
positive correlation between Fas mediated apoptosis and
caspases activation. In HCV infected cells, we observed
a loss of caspases after 4 weeks post HCV infection.
Some studies provided evidence that monitoring of cas-
pases activation might be helpful as a diagnostic tool to
detect the degree of HCV mediated inflammatory liver
damage and to evaluate efficacy of HCV therapy [36,37].
However, it was reported that the extent of caspase acti-
vation correlates with the grade of the disease but not
Table 4 Correlation between gene expression and
clinicopathological features in hepatocellular carcinoma
cases.
Variable
N=3 5
(%)
Bak
N=2 4
(%)
Fas
N=1 9
(%)
FasL
N=8
(%)
Bcl-2
N=2 8
(%)
Bcl-xL
N=9
(%)
Age (mean ± SD)
57 ± 10.2
≤ 55: 16 (46) 12 (75) 7 (44) 3 (19) 10 (63) 5 (31)
> 55: 19 (54) 12 (63) 12 (63) # 5 (26) 18 (95) # 4 (21)
Gender
M: 22 (63) 17 (77) # 12 (55) 5 (23) 19 (86) # 4 (18)
F: 13 (37) 7 (54) 7 (54) 3 (23) 9 (69) 5 (38) #
Tumor size
≤ 8: (22) 14 (64) 10 (45) 4 (18) 17 (77) 5 (23)
> 8: (13) 10 (77) 9 (69) 5 (38) 9 (69) 4 (31)
Grade
II: 22 (63) 16 (73) # 10 (45) 4 (18) 17 (77) 6 (27)
III: 13 (37) 8 (61) 9 (69) # 4 (31) 11 (84) # 3(23)
Invasion
Positive: (18) 15 (83) # 12 (67) 6 (33) 15 (83) 6 (33)
Negative: (17) 9 (53) 7 (41) 2 (12) 13 (76) 3 (18)
Cirrhosis
Present: 15 (43) 8 (53) 10 (67) # 4 (27) 12 (80%) 3 (20)
Absent: 20 (57) 16(80) # 9 (45) 4 (20) 16 (80%) 6 (30)
# significantly difference (p < 0.005)
Table 5 Correlation between gene expression and
clinicopathological features in CH patients
Variable
N=3 4
(%)
Bak
N=1 6
(%)
Fas
N=1 9
(%)
FasL
N=1 6
(%)
Bcl-2
N=2 0
(%)
Age (mean ± SD)
44 ± 9.8
≤ 47: 18 (53) 8 (44) 13 (72) # 8 (44) 9 (50)
> 47: 16 (47) 8 (50) 6 (38) 8 (50) 11 (69)
Gender
M: 31 (91) 13 (41) 17 (55) 15 (48) 18 (58)
F: 3 (8) 3 (100) # 2 (67) # 1 (33) 2 (66)
Steatosis
Absent: (10) 3 (30) 3 (30) 2 (20) 4 (40)
Minimal: (14) 7 (50) 9 (64) 4 (29) 10 (71)
Moderate: (7) 4 (57) 5 (71) 7 (100) 5 (71)
Marked: (3) 2 (67) 2 (67) 3 (100) 1 (33)
Necrosis
Absent: (26) 12 (46) 13 (50) 9 (35) 16 (62)
Minimal: (8) 4 (50) 6 (75) 7 (88) # 4 (50)
Necro-
inflammation
Absent: (10) 4 (40) 5 (50) 0 (0) 3 (30)
Minimal: (15) 8 (53) 9 (60) 8 (53) 11 (73)
Moderate: (9) 4 (44) 5 (56) 8 (89) 6 (67)
Cirrhosis
Present:12 (35) 6 (50) 6 (50) 6(50) 9 (75) #
Absent: 22 (65) 10 (45%) 13 (59) 10(45) 11 (50)
Hepatitis grade
I &II: (26) 11 (42) 12 (46) 9 (35) 15 (58)
III&IV: (8) 5 (63) 7 (88) # 7 (88) # 5 (63)
Hepatitis stage
I &II: (25) 12 (48) 13 (52) 8 (32) 16 (64)
III &IV: (9) 4 (44) 6 (67) 8 (89) # 4 (44)
Bcl-xL was not expressed in any of the studied CH cases. # significantly
difference (p < 0.005).
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viral load [36]. This observation indicates that caspase
activation is not directly related to HCV mediated
damage and suggests the involvement of HCV mediated
immune response with Fas triggered hepatocyte apopto-
sis giving rise to several amplification loops [36]. Similar
findings were reported by others, who indicated in their
study that the core protein could stimulate caspase-
independent apoptosis at later stages of the disease giv-
ing relevance to the release of HCV particles from the
host cells and to viral spread [46].
It has been shown that some HCCs are resistant to
Fas-mediated apoptosis directly through the expression
of HCV proteins or indirectly through up-regulation of
Bcl-2 family members [36]. Our data showed that both
Bcl-2 and Bcl-xL RNA expression were significantly
higher in HCC than in CH and NDT indicating late
involvement of those genes in the cascade of HCV-asso-
ciated hepatocarcinogenesis. We were also able to detect
Bcl-2 gene expression in HepG2 cells starting from day
1 post-infection until the end of the experiment,
whereas the expression of Bcl-xL was not visible until
day 28 when it started to be expressed and its expres-
sion was closely associated with the presence of HCV in
tumor cells (Table 3) suggesting that Bcl-2 is tumor
related whereas Bcl-xL is a viral related. In this context,
Bcl-2 was linked to inhibition of apoptosis via interfer-
ing with either the recruitment of procaspase 8 to Fas
receptors [47] or by preventing the release of cyto-
chrome C [5]. It has also been shown that the HCV
core protein inhibits apoptosis at the mitochondrial
level through augmentation of Bcl-xL expression with
consequent inhibition of caspase 3 activation [16]. The
HCV core protein could induce apoptosis in the Fas
death way although this is achieved through the activa-
tion of Bax and Bak, both are important mediators of
p53 mitochondrial function [5,36]. Our results showed
an increase in Bak-RNA expression at an early stage of
HCV infection of HepG2 cells, which is also observed in
tissue samples obtained from both CH and HCC
patients compared to NDT samples. Our results pro-
vided enough evidence that the Bak gene can induce
apoptosis in HCC cells even in the presence of high
levels of the anti-apoptotic Bcl-2 gene family members,
which is in agreement with the findings of others [48].
The results of gene expression in tissue samples show
a significant correlation between Fas expression in HCC
cases and the presence of cirrhosis or poorly differen-
tiated tumors. We observed that FasL expression was
significantly associated in CH patients with the grade of
inflammation and the stage of fibrosis as well as with
the presence of severe necro-inflammatory changes.
Based on these results we conclude that aberrant
expression of Fas and FasL in HCV-infected patients
could be considered a marker for increased disease
severity with a higher possibility of progression into cir-
rhosis and/or HCC. Similar results were also reported
by others [49], who indicated that FasL may contribute
to malignant transformation of hepatocyte as it was sig-
nificantly expressed in the peri-cancerous lobules and
cirrhotic nodules [42]. Similarly, Bcl-2 expression was
significantly associated with poorly-differentiated tumors
as well as with the presence of cirrhosis in CH patients.
Similar findings were reported previously by some of us
[32]. In this study, Bak expression was significantly asso-
ciated with absence of cirrhosis and well-differentiated
tumors, thus Bak gene could be considered a good prog-
nostic marker.
The impact of HCV infection on modulating apoptotic
machinery pathway(s) differs during the course of infec-
tion, as the disease progresses apoptosis is inhibited
leading to cell immortalization and HCC development.
HCV infection could exert a direct effect on hepatocytes
by inducing Fas-FasL pathway with subsequent inactiva-
tion of caspases or indirectly by immune attack on
hepatocytes resulting in HCV mediated liver injury, viral
persistence and cirrhosis in CH patients with an increas-
ing possibility of hepatocarcinogenesis especially with
increasing proliferation rate and acquisition of genetic
damage.
Alternatively, HCV infection could induce apoptosis at
the early phase of infection followed by modulation of
apoptosis by disturbing Fas/FasL. This in turn would
cause an inactivation of caspases 3, 8, and 9, up-regula-
tion of Bcl-2 family members, impairment in Bak gene
expression and increasing the expression of FasL leading
to inhibition of apoptosis in HCV infected patients. This
signaling cascade favors cell survival with persistence of
HCV infection and enhances the possibility of HCC
development. A combination of these effects initiates a
circle of hepatocyte damage and repair, which is the
hallmark of HCV infection that might progress to HCC.
Our study could provide an insight for understanding
apoptosis and developing molecular target therapies that
could inhibit viral persistence and HCC development.
Further studies are still required to clarify the interac-
tion between other HCV proteins in the apoptotic
machinery system and the possible involvement of other
apoptotic pathways in HCV associated HCC
development.
Conclusions
Chronic HCV infection modulates the apoptotic
machinery differently durin gt h ec o u r s eo fi n f e c t i o n ,
where the virus induces apoptosis early in the course of
infection, and as the disease progresses apoptosis is
modulated. This study could open a new opportunity
for understanding the various signallings of apoptosis
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Page 12 of 14and in the developing a targeted therapy to inhibit viral
persistence and HCC development. Nevertheless, further
studies are mandatory to clarify the interaction between
other HCV proteins in the apoptotic machinery system
and the possible involvement of other apoptotic path-
ways in HCV associated HCC development.
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